Childhood Ependymoma Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (04/02/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment of Newly Diagnosed Childhood Ependymoma, Anaplastic Ependymoma, or RELA Fusion–Positive Ependymoma

Added text to state that the progression-free survival (PFS) for children treated with proton-beam radiation therapy appears to be similar to the PFS for children treated with intensity-modulated photon-beam radiation therapy.

Added text to state that retrospective reviews based on Surveillance, Epidemiology, and End Results data of children younger than 3 years at diagnosis were accrued over a 50-year period. Results showed that patients who received local radiation therapy had better 10-year survival rates, even after adjusting for extent of resection and tumor grade (cited Snider et al. as reference 35).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Treatment of Recurrent Childhood Ependymoma

Next section >
About This PDQ Summary